Deals
Jacobio discovered JAB-23E73, which is designed to treat several KRAS mutation subtypes, and is testing the therapy in multiple Phase I trials.
FEATURED STORIES
2026 is set to be a banner year for M&A in biopharma, as buyers facing major patent cliffs fight for a small pool of late-stage assets.
Metsera showed the biopharma world that M&A is back. Who could be next?
These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Swiss pharma giant Roche acquired Ireland’s Inflazome and its NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases for €380 million (about $451 million) in an upfront payment.
Novus Therapeutics announced on Monday that it had completed its acquisition of Anelixis Therapeutics, a privately held clinical stage biotechnology company.
Grail, a spin out of genome sequencing firm Illumina, filed a preliminary prospectus for a $100 million initial public offering (IPO) last week with the U.S. Securities and Exchange Commission (SEC).
The deal, announced Sunday, has been unanimously approved by the boards of directors of both companies.
It was a busy week for biopharma, biotech and medical device initial public offerings (IPOs). Here’s a look.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
The portfolio is made up of well-established injectable coagulants sold in Europe under various brand names, including Arixtra, Fraxiparine, Mon-Embolex and Orgaran.
Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.
Jayson Dallas, president and chief executive officer of Aimmune, said the agreement with Nestlé recognizes the value of Aimmune’s longtime commitment to advancing therapies for food allergies.
The acquisition is expected to bolster ACADIA’s clinical pipeline to include non-opioid pain therapies that have potential non-addictive properties and reduced side effects typically seen with current opioid treatments.